Literature DB >> 28348035

What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

Hana Golding1, Surender Khurana1, Marina Zaitseva1.   

Abstract

Animal models have played a pivotal role in all stages of vaccine development. Their predictive value for vaccine effectiveness depends on the pathogen, the robustness of the animal challenge model, and the correlates of protection (if known). This article will cover key questions regarding bridging animal studies to efficacy trials in humans. Examples include human papillomavirus (HPV) vaccine in which animal protection after vaccination with heterologous prototype virus-like particles (VLPs) predicted successful efficacy trials in humans, and a recent approval of anthrax vaccine in accordance with the "Animal Rule." The establishment of animal models predictive of vaccine effectiveness in humans has been fraught with difficulties with low success rate to date. Challenges facing the use of animal models for vaccine development against Ebola and HIV will be discussed.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28348035      PMCID: PMC5880166          DOI: 10.1101/cshperspect.a028902

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  76 in total

1.  Ebola vaccine trials: a race against the clock.

Authors:  Gerardo Chowell; Cécile Viboud
Journal:  Lancet Infect Dis       Date:  2015-04-14       Impact factor: 25.071

Review 2.  Immunology of protection from Ebola virus infection.

Authors:  Philip R Krause; Paula R Bryant; Thomas Clark; Walla Dempsey; Erik Henchal; Nelson L Michael; Jason A Regules; Marion F Gruber
Journal:  Sci Transl Med       Date:  2015-05-06       Impact factor: 17.956

3.  IgG Binding Characteristics of Rhesus Macaque FcγR.

Authors:  Ying N Chan; Austin W Boesch; Nana Y Osei-Owusu; Ali Emileh; Andrew R Crowley; Sarah L Cocklin; Samantha L Finstad; Caitlyn H Linde; Rebecca A Howell; Isaac Zentner; Simon Cocklin; Adam R Miles; Joshua W Eckman; Galit Alter; Joern E Schmitz; Margaret E Ackerman
Journal:  J Immunol       Date:  2016-08-24       Impact factor: 5.422

4.  Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.

Authors:  David F Boyd; Dylan Peterson; Beth S Haggarty; Andrea P O Jordan; Michael J Hogan; Leslie Goo; James A Hoxie; Julie Overbaugh
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

5.  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.

Authors:  John M Dye; Andrew S Herbert; Ana I Kuehne; James F Barth; Majidat A Muhammad; Samantha E Zak; Ramon A Ortiz; Laura I Prugar; William D Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

6.  Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

Authors:  Andrew J Bett; Sheri A Dubey; Devan V Mehrotra; Liming Guan; Romnie Long; Kiersten Anderson; Kelly Collins; Christine Gaunt; Rose Fernandez; Suzanne Cole; Steve Meschino; Aimin Tang; Xiao Sun; Sanjay Gurunathan; Jim Tartaglia; Michael N Robertson; John W Shiver; Danilo R Casimiro
Journal:  Vaccine       Date:  2010-10-23       Impact factor: 3.641

7.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

8.  Increased mucosal CD4+ T cell activation in rhesus macaques following vaccination with an adenoviral vector.

Authors:  Irene Bukh; Roberto Calcedo; Soumitra Roy; Diane G Carnathan; Rebecca Grant; Qiuyue Qin; Surina Boyd; Sarah J Ratcliffe; Christin L Veeder; Scarlett L Bellamy; Michael R Betts; James M Wilson
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

9.  Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

Authors:  M Hevey; D Negley; P Pushko; J Smith; A Schmaljohn
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

10.  Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.

Authors:  Susan Zolla-Pazner; Allan deCamp; Peter B Gilbert; Constance Williams; Nicole L Yates; William T Williams; Robert Howington; Youyi Fong; Daryl E Morris; Kelly A Soderberg; Carmela Irene; Charles Reichman; Abraham Pinter; Robert Parks; Punnee Pitisuttithum; Jaranit Kaewkungwal; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Charla Andrews; Robert J O'Connell; Zhi-yong Yang; Gary J Nabel; Jerome H Kim; Nelson L Michael; David C Montefiori; Hua-Xin Liao; Barton F Haynes; Georgia D Tomaras
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

View more
  11 in total

1.  Analyzing Macrophage Infection at the Organ Level.

Authors:  Ryan G Hames; Zydrune Jasiunaite; Joseph J Wanford; David Carreno; Wen Y Chung; Ashley R Dennison; Marco R Oggioni
Journal:  Methods Mol Biol       Date:  2022

Review 2.  The urothelium: a multi-faceted barrier against a harsh environment.

Authors:  Nazila V Jafari; Jennifer L Rohn
Journal:  Mucosal Immunol       Date:  2022-09-30       Impact factor: 8.701

Review 3.  Tissue Engineering Approaches to Uncover Therapeutic Targets for Endothelial Dysfunction in Pathological Microenvironments.

Authors:  Dimitris Ntekoumes; Sharon Gerecht
Journal:  Int J Mol Sci       Date:  2022-07-03       Impact factor: 6.208

4.  Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule.

Authors:  Janice M Rusnak; Lesley C Dupuy; Nancy A Niemuth; Andrew M Glenn; Lucy A Ward
Journal:  Comp Med       Date:  2018-10-03       Impact factor: 0.982

Review 5.  Virus-Like-Vaccines against HIV.

Authors:  Anne-Marie C Andersson; Melanie Schwerdtfeger; Peter J Holst
Journal:  Vaccines (Basel)       Date:  2018-02-11

Review 6.  Control Strategies for Carcinogenic-Associated Helminthiases: An Integrated Overview.

Authors:  José Manuel Correia da Costa; Maria João Gouveia; Gabriel Rinaldi; Paul J Brindley; Júlio Santos; Lúcio Lara Santos
Journal:  Front Cell Infect Microbiol       Date:  2021-03-24       Impact factor: 6.073

7.  Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.

Authors:  Ramon Roozendaal; Jenny Hendriks; Thierry van Effelterre; Bart Spiessens; Liesbeth Dekking; Laura Solforosi; Dominika Czapska-Casey; Viki Bockstal; Jeroen Stoop; Daniel Splinter; Sarah Janssen; Ben van Baelen; Nadia Verbruggen; Jan Serroyen; Eline Dekeyster; Ariane Volkmann; Yvonne Wollmann; Ricardo Carrion; Luis D Giavedoni; Cynthia Robinson; Maarten Leyssen; Macaya Douoguih; Kerstin Luhn; Maria Grazia Pau; Jerry Sadoff; An Vandebosch; Hanneke Schuitemaker; Roland Zahn; Benoit Callendret
Journal:  NPJ Vaccines       Date:  2020-12-17       Impact factor: 7.344

8.  Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans.

Authors:  Marija Zaric; Arianna Marini; Carolyn M Nielsen; Gaurav Gupta; David Mekhaiel; Thao P Pham; Sean C Elias; Iona J Taylor; Hans de Graaf; Ruth O Payne; Yuanyuan Li; Sarah E Silk; Chris Williams; Adrian V S Hill; Carole A Long; Kazutoyo Miura; Sumi Biswas
Journal:  Front Immunol       Date:  2021-09-30       Impact factor: 7.561

9.  A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.

Authors:  Jihyun Yang; Eunjin Kim; Jong-Soo Lee; Haryoung Poo
Journal:  Vaccines (Basel)       Date:  2021-06-11

Review 10.  Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines.

Authors:  Chun-Wei Chen; Narcís Saubi; Joan Joseph-Munné
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.